Cargando…
Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers
The in vivo potency of antisense oligonucleotides (ASO) has been significantly increased by reducing their length to 8–15 nucleotides and by the incorporation of high affinity RNA binders such as 2′, 4′-bridged nucleic acids (also known as locked nucleic acid or LNA, and 2′,4′-constrained ethyl [cET...
Autores principales: | Subramanian, Romesh R., Wysk, Mark A., Ogilvie, Kathleen M., Bhat, Abhijit, Kuang, Bing, Rockel, Thomas D., Weber, Markus, Uhlmann, Eugen, Krieg, Arthur M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627098/ https://www.ncbi.nlm.nih.gov/pubmed/26446989 http://dx.doi.org/10.1093/nar/gkv992 |
Ejemplares similares
-
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021) -
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
por: Prakash, Thazha P, et al.
Publicado: (2019) -
Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides
por: Yoshida, Tokuyuki, et al.
Publicado: (2022) -
Controlled sulfur-based engineering confers mouldability to phosphorothioate antisense oligonucleotides
por: Genna, Vito, et al.
Publicado: (2023) -
Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
por: Alharbi, Arwaf S, et al.
Publicado: (2020)